Functions and applicable groups of Opicapone capsules

Opicapone is a new, long-acting COMT inhibitor. Its main function is to prolong the "on period" (i.e., the time for symptom relief) after Parkinson's disease patients take levodopa, and effectively control the "off period" phenomenon. Compared with traditional COMT inhibitors such as entacapone, opicapone has higher enzyme binding capacity and longer half-life, giving it the advantage of maintaining stable efficacy with once-daily administration, reducing patient medication frequency and improving compliance.

The core mechanism of action of Opicapone is to inhibit peripheral COMT enzyme activity, preventing levodopa from being rapidly metabolized into inactive 3-methoxydopa (3-OMD) in the blood, thereby increasing the concentration of levodopa entering the central nervous system. This mechanism is particularly important for patients with intermediate and advanced Parkinson's disease, who often experience dose fluctuations, "switching phenomena" or movement fluctuations due to prolonged use of levodopa. By prolonging the action time of levodopa, Opicapone can significantly reduce the "off period" time and improve the stability of exercise ability.

In terms of the applicable population, Opicapone is mainly suitable for adult patients with Parkinson's disease who require combined levodopa treatment and experience motor fluctuations, especially those who have poor tolerance to traditionalCOMT inhibitors or who need a simplified medication regimen. Due to its lower risk of hepatotoxicity and good pharmacokinetic performance, it is also suitable for elderly patients who want to reduce drug-related side effects. In practical clinical applications, Opicapone also shows good tolerance. The most common side effects are hyperkinesia, constipation and dry mouth, which can generally be adapted to in a short period of time.

In summary, Opicapone capsules, as an important part of the adjuvant treatment of Parkinson's disease, provide a new treatment path to solve the "switch fluctuation" problem, and are especially suitable for patients with unstable levodopa basic treatment effects.

Reference materials:https://www.ongentys.com/